NEW YORK (GenomeWeb) – Myriad Genetics reported after the close of the market on Tuesday that its fiscal fourth quarter revenues rose 1 percent year over year, thanks largely to a 6 percent increase in pharmaceutical and clinical service revenues, which offset flat molecular diagnostic testing revenues.

For the three months ended June 30, the firm reported total revenues of $200.9 million, up from $199.6 million in fiscal Q4 2017, and beating the consensus Wall Street estimate of $195.8 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The World Health Organization has announced the members of its gene-editing committee, according to NPR.

DARPA is working on developing algorithms that gauge the credibility of research findings, Wired reports.

The American Society of Breast Surgeons recommends all women diagnosed with breast cancer be offered genetic testing, the Washington Post says.

In Science this week: comparison of modern, historical rabbit exomes uncovers parallel evolution after myxoma virus exposure; and more.